Feeling the tension: Engineered stem cells convert tumor stiffness into a drug target.

Engineered mesenchymal stem cells convert tumor stiffness into a detectable and targetable marker, enabling PET imaging and radionuclide therapy in previously untargetable tumors.

• Why it matters: Many tumors lack validated molecular targets, limiting the effectiveness of radiopharmaceutical theranostics and restricting treatment options for certain cancers.
• What they did: Yang et al. engineered mesenchymal stem cells that detect tumor stiffness and produce a synthetic target in response, facilitating the use of existing radioligands for imaging and therapy.
• The result: This approach transforms the tumor microenvironment into a drug target, expanding theranostic possibilities and potentially improving treatment outcomes for hard-to-target tumors.